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Abstract
Variant forms of the plasma protein transthyretin (TTR) are associated with the most frequently occurring type of familial
systemic amyloidosis. Organ system involvement in transthyretin type amyloidosis (ATTR) is often similar to that which
occurs in light chain amyloid disease (AL). The proper diagnosis of ATTR is important since treatment (liver
transplantation) differs from that in AL (chemotherapy). We present a two-step test to screen sera for variant TTRs
using non-denaturing gel electrophoresis performed in 7.5% acrylamide (PAGE) followed by isoelectric focusing (IEF)
between pH 4.0 and 7.0 in 2.5 M urea. Serum samples from 110 patients with amyloidosis and their relatives were tested using
this IEF technique and compared to genetic mutation results. Sera from patients with ATTR who underwent liver
transplantation were also examined prior to and following surgery. IEF analysis showed the presence of both wild-type and
variant TTR in 74 of the 110 serum samples tested. Genomic DNA from peripheral blood was used to identify TTR gene
mutations in 77 of the 110 patients. Fifteen variants including Val122Ile, preponderant in the African-American population,
could be demonstrated by IEF. The sensitivity of IEF was 96% (74/77) and the specificity was 100% (33/33). The predictive
values for a positive or negative result were 100% (74/74) and 92% (33/36), respectively. There were no false-positive results
and 4% (3/77) false-negative results. In sera from patients with ATTR who underwent liver transplantation, variant TTR was
detected by IEF before, but not after, surgery. A simple, accurate, sensitive method is presented as a useful screening test for
variant transthyretins associated with ATTR. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Familial amyloidosis due to a variant transthyretin
(ATTR) is the most common of the inherited sys-
temic amyloidoses [1^6]. Onset of ATTR, an autoso-
mal dominant disease, usually occurs in the third to
¢fth decade with symptoms of peripheral neuropa-
thy, autonomic neuropathy and/or cardiomyopathy.
The clinical features of ATTR are often indistin-
guishable from those of primary, or light-chain amy-
loidosis (AL). Since the prognoses and treatments are
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quite di¡erent in the two diseases, an accurate diag-
nosis of amyloid type is important. Untreated pa-
tients with AL survive only months following dis-
ease onset, while those with ATTR can live 7^15
years with disease. Treatment for patients with
AL is often chemotherapy, sometimes accompanied
by autologous stem cell transplantation. Treatment
for patients with ATTR is liver transplantation
[7^10].
The plasma protein transthyretin (TTR), normally
a transport molecule for thryroxine and retinol, is a
tetramer composed of four identical, non-covalently
associated subunits. Each monomer is composed of
127 amino acid residues and has a molecular weight
(Mr) of approximately 14 000 Da [11,12]. While a few
non-pathologic isoforms of TTR have been charac-
terized [13,14], over 50 di¡erent TTR variants have
been identi¢ed in the plasma and tissue deposited
amyloid of patients with ATTR [5]. The mechanism
of amyloid ¢bril formation and deposition in ATTR
is not known. Conformational changes due to amino
acid substitutions are thought to destabilize TTR’s
molecular structure causing aggregation, possibly
through the formation of non-native intermediate
species [15]. These intermediates may arise from de-
stabilization of the tetramer as the result of partial
monomer unfolding [16^18]. It has also been sug-
gested that certain substitutions cause a reduced sus-
ceptibility to proteolysis [19]. Aggregation is thought
to occur following a rate-limiting nucleation step and
then proceed as ordered ¢lament growth with resul-
tant amyloid ¢bril precipitation and tissue deposition
[20].
This report describes a rapid, cost-e¡ective and
simple two-step method, performed with equipment
available in most clinical laboratories, to separate
wild-type and variant TTR isoforms. Using a mod-
i¢cation of the methodology described by Altland
and colleagues [21^23], native polyacrylamide gel
electrophoresis (PAGE) followed by isoelectric fo-
cusing (IEF) under partially denaturing conditions,
was used to assay 110 sera for the presence of
TTR variants. The IEF data was compared to ge-
netic testing results. The method was also used to
examine sera collected from patients with ATTR
prior to and following liver transplantation treat-
ment.
2. Materials and methods
2.1. Samples
Blood was collected from patients referred to the
Boston Medical Center Amyloid Program after re-
ceiving approval by the Institutional Review Board
and informed consent from the patients. Only pa-
tients known to have ATTR (and their relatives) or
those whose type of amyloid disease (AL or ATTR)
was undetermined were included in this study. In all
cases, amyloid disease was con¢rmed by a positive
Congo red tissue biopsy. Serum for IEF and periph-
eral lymphocytes for DNA mutation analysis were
isolated from collected blood samples and tested ei-
ther immediately or within 3 weeks. Prior to analy-
ses, sera and lymphocytes were stored at 320 and
380‡C, respectively. Several serum samples were re-
tested by IEF after being frozen for up to 3 years.
Serum samples obtained at multiple time points be-
fore and after surgery from each of more than 10
patients who underwent liver transplantation were
also examined.
2.2. Isoelectric focusing procedure
A two-step procedure using native PAGE followed
by IEF under partially denaturing conditions was
performed. Native PAGE was carried out on a
7.5% acrylamide gel (11.5U10 cm, 1.5 mm thick)
containing up to 10 wells. The gel was prerun at 35
mamp prior to sample loading in a two-bu¡er system
consisting of 0.06% (v/v) Bromophenol blue (from
saturated stock solution) in 0.04 M glycine, 0.4 M
Tris-HCl, pH 8.9 (upper bu¡er) and 0.12 M Tris-
HCl, pH 8.08 (lower bu¡er). The gel was electro-
phoresed until the dye front from the upper bu¡er
reservoir was approximately 3 cm from the bottom
of the gel. Fifty Wl of each serum sample was loaded
onto the native gel in non-adjacent wells (each sam-
ple was sandwiched by empty wells for clarity), elec-
trophoresed at 30 mamp (constant current) until the
samples had migrated to within 2 cm of the dye
front. Puri¢ed human TTR (Calbiochem-Behring,
La Jolla, CA) was used as a control on one end of
the gel. This sample lane was cut o¡ and stained with
Coomassie blue to visualize the TTR band. In the
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remaining portion, a 1 cmU8 cm (widthUlength)
horizontal gel strip aligned with the stained commer-
cial TTR band was excised and equilibrated in 2.5 M
urea for 30 min.
The gel strip containing the partially puri¢ed TTR
samples was then subjected to a second electropho-
resis step by IEF on a broad range (pH 4.0^7.0)
Immobiline gel (Pharmacia Biotech, Uppsala, Swe-
den). The Immobiline gel was rehydrated for 2 h in
2.5 M urea, 6% dextran, 8.1% Pharmalyte (pH 5^6),
50 mM DTT using a reswelling cassette (Pharmacia)
prior to electrophoresis. Electrode wicks (Pharmacia)
were oriented on the proper sides of the gel after
being presoaked in the appropriate bu¡ers. The ano-
dal wick was immersed in 0.01 M acetic acid, pH 3.2,
while the cathodal wick was soaked in 0.01 M Tris-
HCl, pH 7.7. After the wicks were in place, the 1 cm
wide gel strip was positioned adjacent to the catho-
dal wick and electrophoresed at 2500 V for a mini-
mum of 6 h at room temperature on a water cooled
Multiphor Electrophoresis Unit (Pharmacia). Fol-
lowing electrophoresis, the IEF gel was ¢xed in
20% trichloroacetic acid for 1 h, rinsed in deionized
H2O and equilibrated in 25% ethanol, 8% acetic acid
(destaining solution). The gel was placed in pre-
warmed Coomassie blue staining solution at 60‡C
for 20^30 min, destained in 25% ethanol, 8% acetic
acid and ¢nally treated for 30 min in a preserving
solution of 25% ethanol, 8% acetic acid, 10% glycer-
ol. Gels were stored inde¢nitely wrapped in cello-
phane sheets containing preserving solution.
2.3. DNA mutation analysis
DNA mutation analysis was performed on those
individuals who either had a family history sugges-
tive of ATTR or in whom the diagnosis of another
type of amyloidosis was not clearly established. Ge-
netic testing by restriction fragment length polymor-
phism (RFLP) and/or DNA sequencing was carried
out on genomic DNA isolated from peripheral blood
lymphocytes. Regions of the TTR gene containing
exons 2, 3 and 4 were ampli¢ed by PCR as described
previously [24]. PCR products were either sequenced
directly or electrophoresed in polyacrylamide gels to
assay for the gain or loss of restriction endonuclease
cleavage sites following enzymatic treatment [24,25].
Exon 2 product was incubated with endonucleases
HgaI, NsiI, CfoI, Sau96, MspI, BclI, DdeI, HaeIII,
HinfI. Cys10Arg, Val30Met, Val30Ala, Val30Leu,
Val30Gly, Phe33Ile, Phe33Leu, Glu42Gly and Ala-
45Asp substitutions are detected by this procedure.
The non-pathogenic Gly6Ser will also be identi¢ed
with MspI.
Exon 3 product was incubated with BsrI, HinfI,
AluI, BanII, ApoI, DraIII, AciI, AccI and SspI.
Ser50Ile, Ser50Arg, Ser52Pro, Glu54Gly, Leu55Pro,
Leu58His, Leu58Arg, Thr60Ala, Phe64Leu, Tyr69His,
Val71Ala, Ile73Val, Ser77Tyr and Ile84Asn substitu-
tions are demonstrated in this way.
Exon 4 product was incubated with BsrDI, DdeI
and MaeIII to detect Ile107Val and Val122Ile.
2.4. Statistical analysis
IEF and genetic testing results were compared to
obtain measurements of sensitivity and speci¢city of
IEF screening as well as to de¢ne the predictive value
for a positive or negative result [26].
3. Results
IEF screening of 110 sera demonstrated that 74
samples had two TTR bands, one which migrated
to a position that was identical to wild-type TTR
alone. Thirty-six samples had a single TTR band
which occurred at a migration position consistent
with wild-type TTR. This indicated that 74/110 sam-
ples contained one variant TTR isoform in addition
to the wild-type protein. Repetitive testing of the
samples, some that had been frozen for up to 3 years,
gave reproducible results.
In the group of 74 samples that showed two TTR
bands by IEF, 15 di¡erent electrophoretic migration
patterns were noted. The electrophoretic migration
endpoint of wild-type TTR measured a constant dis-
tance from the application point in all samples. The
occurrence of variant TTR bands deviated in dis-
tance from the position of the wild-type band and
resulted in 15 patterns. Genetic analysis by RFLP
and/or DNA analysis of matched samples from these
74 cases identi¢ed mutations which corresponded to
the following 15 variant TTR isoforms: Val30Ala,
Val30Met, Phe33Leu, Ala36Pro, Glu42Gly/His90Asn,
Ala45Thr, Leu58His, Thr60Ala, Phe64Leu, Val71Ala,
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Ile73Val, Ser77Tyr, Ile84Asn, Glu89Gln, and Val122Ile.
An example of each IEF two-band pattern and the
TTR variant it represents is illustrated in Fig. 1
along with a sample containing wild-type TTR ex-
clusively. Patterns for sera containing the same TTR
variant were identical, and in all 74 cases the IEF
results were consistent with the genetic data. In 14/
15 patterns, the variant isoform appeared electrolyti-
cally more basic than the wild-type TTR, i.e. it had a
more delayed or cathodal migration indicating a di-
minution of overall net negative charge as compared
to that of the wild-type species. One isoform (identi-
¢ed as Val122Ile from RFLP analysis) displayed a
more acidic pI, i.e. a more anodal migration pattern
than wild-type TTR. The greatest di¡erence in mi-
gration distance between variant and wild-type TTR
was noted for the Leu58His variant.
Fifty non-related kinships are represented in the
group of 74 samples with two TTR bands by IEF.
The distribution of kinships among the 15 di¡erent
TTR variants is shown in Table 1. Four of the var-
iants represent 39 non-related kinships. Val30Met
was the most common TTR isoform with 25 samples
from 19 kinships followed by 16 samples from 10
kinships with Thr60Ala, nine samples from six kin-
ships with Leu58His, and four samples from four
unrelated individuals with Val122Ile. Five samples
from one family with the double mutation
Glu42Gly/His90Asn were analyzed. The other 10 var-
iants were representative of a single kinship in each
Fig. 1. IEF patterns demonstrating wild-type (arrow) and variant TTR protein bands from 15 patients with ATTR, as well as a non-
ATTR individual (normal). For ease of visualization, lanes 1^15 are labeled with the variant amino acid and residue position noted.
The neutral to acidic pH gradient runs from top (pH 7) to bottom (pH 4). (A) Lanes 1^10 show TTR variants that commonly occur
in ATTR including Val30Met (lane 2), Leu58His (lane 7), and Thr60Ala (lane 8). The Glu42Gly variant (lane 5) also contains a non-
pathologic mutation, His90Asn, on the same allele. (B) Lanes 11^16 demonstrate additional TTR isoforms associated with ATTR in-
cluding the Val122Ile variant (lane 15) which has a high incidence in the African- American population, as well as the IEF pattern of
a non-ATTR serum (lane 16) which shows only one band corresponding to wild-type TTR.
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case with samples obtained on either one or two
related individuals.
Genetic testing demonstrated the presence of TTR
mutations in a total of 77 cases. Seventy-four of
these (as reported in the preceding paragraphs)
yielded IEF results that were consistent with the ge-
netic data. Three additional cases containing hetero-
zygous TTR alleles identi¢ed by mutation analysis
showed only one TTR band on IEF testing. DNA
screening identi¢ed a point mutation which corre-
sponded to Tyr69His in two of the cases and a double
mutation in the third case which coded for Gly6Ser/
Tyr114Cys variant TTR.
The results obtained by IEF testing and DNA
analysis were compared to determine the sensitivity
and speci¢city of IEF as a screening procedure (Ta-
ble 2). The presence of two TTR bands on IEF was
designated a positive result as was the detection of a
TTR mutation by genetic testing. Seventy-four of the
77 DNA positive samples showed two bands by IEF
demonstrating a sensitivity of 96%. All of the 33
DNA negative samples exhibited one band by IEF
indicating a speci¢city of 100%. The predictive value
for a positive result was 100% (74/74), while the pre-
dictive value for a negative result was 92% (33/36).
There were no false-positive results and 3/77 false-
negative results (4%).
TTR analysis by IEF was performed on serum
samples obtained at multiple time points before
and after surgery from each of more than 10 patients
who underwent liver transplantation as treatment for
their disease. Three representative cases are shown
with samples taken prior to and at varying time
points following the surgery (Fig. 2). In each case,
the appearance of a TTR variant was apparent pre-
transplantation and absent at all time points tested
postsurgery.
Table 1
Sample and kinship distribution of 74 IEF positive serum sam-
ples among the 15 TTR variants tested

















Sensitivity and speci¢city of IEF based on results from DNA analysis
IEF DNA analysis Total
Mutation detected (+) No mutation detected (3)
Two bands (+) 74 0 74
One band (3) 3 33 36
Total 77 33 110
Fig. 2. IEF of pre- and post-transplantation serum samples
from three ATTR patients, two with circulating Val30Met TTR
variant pretransplantation and one who had the doubly substi-
tuted Glu42Gly/His90Asn TTR isoform before surgery. Both
wild-type (arrow) and variant isoforms of TTR are seen in all
three patients before liver transplantation (indicated as Pre).
There is no evidence of variant following surgery (indicated as
Post) by IEF in the three cases. Postsurgery sera shown (left to
right) were drawn at 8 days, 1 year and 1.5 years, respectively.
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4. Discussion
Genetic testing for TTR mutations is the method
most often used to identify TTR variants associated
with ATTR [27]. Alternative techniques have in-
cluded mass spectroscopy [28,29] and radioimmuno-
assay [30]. In addition, Altland et al. have demon-
strated several TTR variants with IEF using gel
preparations and technical conditions (including
urea concentrations) that are customized to the iso-
forms being studied [21^23]. The IEF methodology
presented in this report o¡ers several advantages as a
screening test for variant TTRs in that it is rapid,
reproducible, and requires only 50 Wl of serum. The
use of reagents/materials that are commercially avail-
able eliminates the laborious preparation of IEF gels
and allows consistency. The equipment required for
testing is common to most laboratories and the re-
sults obtained are easy to interpret. The conditions
of the procedure are never varied. On native PAGE,
wild-type and all isoforms of TTR migrate contigu-
ously with the dye front and more rapidly than all
other human serum proteins. The partially puri¢ed
TTR is then electrophoresed under partially denatur-
ing conditions in a limited pH range by IEF. Wild-
type TTR has a pI of 5.5 in 2.5 M urea and normal
serum will demonstrate one discreet band in this pH
region. The visualization of two bands unequivocally
indicates the presence of a variant TTR species in
addition to the wild-type TTR protein.
The sensitivity of this technique is 96% when IEF
testing and DNA mutation analysis results are com-
pared. A variant TTR that di¡ers from the wild-type
protein by only one amino acid can be detected.
Substitutions which involve charged amino acids
(Glu89Gln) would be expected to dramatically in£u-
ence the pI of the protein by altering the net molec-
ular charge on TTR, thereby allowing simple detec-
tion by IEF analysis. However, it was also possible
to detect electrically neutral substitutions (Val30Met)
using IEF. It has been suggested that the pI shift in
the case of Val30Met is due to the close proximity of
histidine (position 31) which may e¡ect a change in
the overall charge on the variant TTR molecule
[21,22]. This detection capability is important in
identifying uncommon or unreported TTR variants
that would otherwise require single-strand conforma-
tion polymorphism (SSCP) analysis or gene sequenc-
ing for identi¢cation [31]. The 6 100% (96%) level of
sensitivity for IEF testing re£ects the fact that two
TTR isotypes (three samples) could not be conclu-
sively demonstrated in this assay. These three cases
which appeared to have only wild-type TTR by IEF
when analyzed by genetic testing were shown to con-
tain TTR mutations. In one patient, the double mu-
tation which corresponds to Gly6Ser/Tyr114Cys was
identi¢ed while in the other two cases, the presence
of Tyr69His was genetically determined. Failure to
detect Tyr114Cys by IEF has been reported by others
[32].
A single band by IEF testing could result from the
presence of either homozygous wild-type TTR or
homozygous variant TTR. It would be expected
that the presence of only variant TTR would be de-
tected as a single band by IEF at a position other
than where wild-type TTR occurs. This was not ob-
served in any of the samples tested in this study. A
third possibility for observing a single band would be
the presence of a mixture of wild-type and variant
proteins which contained undetectably low levels of
one isoform or a TTR variant which could not be
resolved by this IEF method. In the three cases men-
tioned above, further analysis of each serum using
mass spectrometric techniques (data not shown)
failed to demonstrate the presence of a variant spe-
cies suggesting that indeed circulating variant TTR
concentrations in these samples were extremely low
and beyond the detection limits of IEF.
The speci¢city of IEF testing is 100%. In addition,
comparison of IEF results with those from genetic
mutation analysis indicated that a positive IEF result
has a 100% predictive value for the presence of a
variant TTR. The predictive value is the most impor-
tant measure of a test’s performance for the clinician.
A positive test result indicates a patient has a variant
TTR, and thus has or is predisposed to ATTR.
The predictive value of a negative IEF result is
92% re£ecting the two TTR variants (three cases
previously discussed) that were not detected using
this technique. Samples that tested negative both by
IEF and genetic analyses were from persons whose
symptoms made them suspect for a variant TTR but
were eventually found to have other forms of amy-
loid, or asymptomatic individuals with no diagnosis
of amyloid who were relatives of patients with
ATTR.
BBADIS 61742 21-8-98
L.H. Connors et al. / Biochimica et Biophysica Acta 1407 (1998) 185^192190
The signi¢cance of this procedure lies in its poten-
tial as a screening test for clinicians to identify pa-
tients with a variant TTR [33]. A tissue biopsy is
necessary to make the diagnosis of amyloidosis, but
it does not determine the type. Since AL amyloidosis
is more common, tests to con¢rm a plasma cell dys-
crasia diagnostic of AL are initially performed. If
these results are negative, testing for a variant TTR
is the critical next step in determining a diagnosis of
ATTR. Alternatively, detection of a variant TTR
leads the physician to strongly suspect ATTR and
con¢rmation of this can then be made by identifying
a mutation associated with familial amyloidosis
through DNA testing. A family history of amyloido-
sis may not always be present in patients with
ATTR, particularly when disease onset is at a later
age. It has recently been reported that a high inci-
dence of the mutation which translates for the
Val122Ile variant is present in the African-American
population [34]. The prevalence of Val122Ile in this
group may be as high as 3.9% in the United States
[35]. The four cases of Val122Ile presented in this
report were identi¢ed in patients hospitalized with
heart failure at our institution and not from a large
referral population.
In summary, this report demonstrates the use of
IEF, a simple, accurate, sensitive test that can be
successfully performed in any laboratory, as a
screening test for variant forms of TTR associated
with ATTR. We have demonstrated the presence of
15 di¡erent TTR isoforms in 74 serum samples
from individuals with ATTR and relatives at risk
for the disease. Four of the variants that are easily
assessed using this procedure, Val30Met, Val122Ile,
Thr60Ala and Leu58His have been reported to be
the most commonly occurring pathogenic forms of
TTR in the world-wide population of patients with
ATTR.
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